# Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA

> **NCT05922839** · PHASE2 · UNKNOWN · sponsor: **Chen Miao** · enrollment: 22 (estimated)

## Conditions studied

- Warm Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT05922839
- **Lead sponsor:** Chen Miao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-11
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2024-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05922839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05922839, "Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05922839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*